Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: A meta-analysis of randomised, controlled trials

British Journal of Nutrition

Volumn 108, Issue 3, 2012, Pages 400-407

  Pan, Yu ^a,b   Guo, Li Li ^a   Cai, Ling Ling ^a   Zhu, Xiao Juan ^a   Shu, Jin Lian ^a   Liu, Xiao Li ^a   Jin, Hui Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Chronic kidney disease; CVD; Folic acid; Homocysteine; Homocysteine lowering therapy; Meta analyses

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS; PERITONEAL DIALYSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865269283     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511007033     Document Type: Review

References (40)

1. Cheung AK, Sarnak MJ, Yan G, et al. (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 65, 2380-2389. (Pubitemid 38670024)
2. Sarnak MJ, Levey AS, Schoolwerth AC, et al. (2003) Kidney disease as a risk factor for the development of cardiovascular disease. Circulation 108, 2154-2169.
3. Go AS, Chertow GM & Fan D (2004) Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296-1305.
4. Eikelboom JW, Lonn EM, Genest J, et al. (1999) Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131, 363-375. (Pubitemid 29424631)
5. Bayes B, Pastor MC, Bonal J, et al. (2005) New cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int Suppl S39-S43. (Pubitemid 40019214)
6. Wollesen F, Brattstrom B, Refsum H, et al. (1999) Plasma total homocysteine and cystein in relation to glomerular filtration rate. Kidney Int 55, 1028-1035. (Pubitemid 29100715)
7. Mallamaci F, Zoccali C, Tripepi G, et al. (2002) Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61, 609-614. (Pubitemid 34102603)
8. Buccianti G, Baragetti I, Bamonti F, et al. (2004) Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 17, 405-410. (Pubitemid 39106906)
9. Lonn E, Yusuf S, Arnold MJ, et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567-1577.
10. Bazzano LA, Reynolds K, Holder KN, et al. (2006) Effect of folic acid supplementation on the risk of cardiovascular diseases. JAMA 296, 2720-2726.
11. SulimanME, Lindholm B, Barany P, et al. (2007) Homocysteinelowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial 20, 523-529.
12. Zoungas S, McGrath BP, Branley P, et al. (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure - a multicenter, randomized, controlled trial. J Am Coll Cardiol 47, 1108-1116.
13. Wrone EM, Homberger JM, Zehnder JL, et al. (2004) Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J Am Soc Nephrol 15, 420-426. (Pubitemid 38140783)
14. Righetti M, Serbelloni P, Milani S, et al. (2006) Homocysteinelowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24, 379-386. (Pubitemid 44215183)
15. Qin X, Huo Y, Langman CB, et al. (2011) Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 6, 482-488.
16. Righetti M, Ferrario GM, Milani S, et al. (2003) Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 9, PI19-PI24. (Pubitemid 36565380)
17. Vianna AC, Mocelin AJ, Matsuo T, et al. (2007) Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11, 210-216. (Pubitemid 46534555)
18. Nanayakkara PW, van Guldener C, ter Wee PM, et al. (2007) Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167, 1262-1270. (Pubitemid 46998497)
19. Mann JFE, Sheridan P, McQueen MJ, et al. (2008) Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease - results of the renal Hope-2 study. Nephrol Dial Transplant 23, 645-653. (Pubitemid 351767601)
20. Jamison RL, Hartigan P, Kaufman JS, et al. (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 1163-1170. (Pubitemid 47403102)
21. House AA, Eliasziw M, Cattran DC, et al. (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603-1609.
22. Heinz J, Kropf S, Domröse U, et al. (2010) B-vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease results of a randomized controlled trial. Circulation 121, 1432-1438.
23. Widlansky ME, Gokce N, Keaney JF, et al. (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42, 1149-1160. (Pubitemid 37188333)
24. Schachinger V, Britten MB & Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906. (Pubitemid 30225269)
25. Tatematsu S, Wakino S, Kanda T, et al. (2007) Role of nitric oxide producing and degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18, 741-749. (Pubitemid 46434491)
26. van Guldener C, Janssen MJ, Lambert J, et al. (1998) Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after longterm therapy. Perit Dial Int 18, 282-289. (Pubitemid 28365120)
27. van Guldener C, Janssen MJ, Lambert J, et al. (1998) No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in hemodialysis patients. Nephrol Dial Transplant 13, 106-112. (Pubitemid 28033588)
28. Arnadottir M, Gudnason V & Hultberg B (2000) Treatment with different doses of folic acid in hemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 15, 524-528. (Pubitemid 30160660)
29. Boushey CJ, Beresford SA, Omenn GS, et al. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049-1057.
30. Tremblay R, Bonnardeaux A, Geadah D, et al. (2000) Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 58, 851-858. (Pubitemid 30620035)
31. Billion S, Tribout B, Cadet E, et al. (2002) Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrol Dial Transplant 17, 455-461. (Pubitemid 34211143)
32. Födinger M, Mannhalter C, Wölfl G, et al. (1997) Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52, 517-523. (Pubitemid 27359598)
33. House AA, Wells GA, Donnelly JG, et al. (2000) Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 15, 1029-1034. (Pubitemid 30410376)
34. Biasioli S, Schiavon R, Petrosino L, et al. (1998) Dialysis kinetics of homocysteine and reactive oxygen species. ASAIO J 44, M423-M432. (Pubitemid 28468869)
35. Galli F, Benedetti S, Buoncristiani U, et al. (2003) The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 64, 748-755. (Pubitemid 36871951)
36. Mudge DW, Rogers R, Hollett P, et al. (2005) Randomized trial of FX high flux vs. standard high flux dialysis for homocysteine clearance. Nephrol Dial Transplant 20, 2178-2185. (Pubitemid 41510095)
37. Helal I, Smaoui W, Hamida FB, et al. (2010) Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl 21, 59-62.
38. Mehrabi MR, Huber K, Serbecic N, et al. (2002) Enrichment of homocysteine in coronary arteries of patients with coronary artery disease. Thromb Res 107, 189-196.
39. Jadad AR, Moore RA, Carroll D, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1-12. (Pubitemid 26120810)
40. Ebbing M, Bønaa KH, Nygård O, et al. (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302, 2119-2126.